CÁNCER DE MAMA
Universitat de Barcelona
Barcelona, EspañaPublications en collaboration avec des chercheurs de Universitat de Barcelona (10)
2022
-
Safety and efficacy of ribociclib plus letrozole in patients with HR+, HER2– advanced breast cancer: Results from the Spanish sub-population of the phase 3b CompLEEment-1 trial
Breast, Vol. 66, pp. 77-84
-
Stromal oncostatin M cytokine promotes breast cancer progression by reprogramming the tumor microenvironment
Journal of Clinical Investigation, Vol. 132, Núm. 7
2019
-
A phase Ib study of sonidegib (LDE225), an oral small molecule inhibitor of smoothened or Hedgehog pathway, in combination with docetaxel in triple negative advanced breast cancer patients: GEICAM/2012–12 (EDALINE) study
Investigational New Drugs, Vol. 37, Núm. 1, pp. 98-108
2017
-
Resistance to Taxanes in Triple-Negative Breast Cancer Associates with the Dynamics of a CD49f+ Tumor-Initiating Population
Stem Cell Reports, Vol. 8, Núm. 5, pp. 1392-1407
2016
-
Measurement of total and free docetaxel concentration in human plasma by ultra-performance liquid chromatography-tandem mass spectrometry
Journal of Pharmaceutical and Biomedical Analysis, Vol. 117, pp. 140-149
2015
-
Population-based multicase-control study in common tumors in Spain (MCC-Spain): Rationale and study design
Gaceta Sanitaria, Vol. 29, Núm. 4, pp. 308-315
2014
-
Effect of a diet and physical activity intervention on body weight and nutritional patterns in overweight and obese breast cancer survivors
Medical Oncology, Vol. 31, Núm. 1
-
VAV3 mediates resistance to breast cancer endocrine therapy
Breast Cancer Research, Vol. 16, Núm. 3
2012
-
RANK induces epithelial-mesenchymal transition and stemness in human mammary epithelial cells and promotes tumorigenesis and metastasis
Cancer Research, Vol. 72, Núm. 11, pp. 2879-2888
2009
-
Novel inhibitors of fatty acid synthase with anticancer activity
Clinical Cancer Research, Vol. 15, Núm. 24, pp. 7608-7615